Systemic thrombolysis with rt-PA is contraindicated in patients with acute ischemic stroke anticoagulated with dabigatran. This expert opinion provides guidance on the use of the specific reversal agent idarucizumab followed by rt-PA and/or thrombectomy in patients with ischemic stroke pre-treated with dabigatran. The use of idarucizumab followed by rt-PA is covered by the label of both drugs.
JauchECSaverJLAdamsHPJr. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2013; 44: 870–947.
2.
PrabhakaranSRuffIBernsteinRA. Acute stroke intervention: a systematic review. JAMA2015; 313: 1451–1462.
3.
GoyalMMenonBKvan ZwamWH. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet2016; 387: 1723–1731.
4.
JuttlerESchwabSSchmiedekP. Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial. Stroke2007; 38: 2518–2525.
5.
SczesniKCWiebringhausRHeuserLSkoddaSEydingJ. Mechanical thrombectomy – an alternative treatment option in a patient with acute ischemic stroke and multiple contraindications for systemic thrombolysis: a case report. J Med Case Rep2013; 7: 256.
6.
RebelloLCHaussenDCBelagajeSAndersonAFrankelMNogueiraRG. Endovascular treatment for acute ischemic stroke in the setting of anticoagulation. Stroke2015; 46: 3536–3539.
7.
PurruckerJCWolfMHaasK. Safety of Endovascular thrombectomy in patients receiving non-vitamin k antagonist oral anticoagulants. Stroke2016; 47: 1127–1130.
8.
ConnollySJEzekowitzMDYusufS. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med2009; 361: 1139–1151.
9.
SchieleFvan RynJCanadaK. A specific antidote for dabigatran: functional and structural characterization. Blood2013; 121: 3554–3562.
10.
GlundSStangierJSchmohlM. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet2015; 386: 680–690.
11.
PollackCVJrReillyPAEikelboomJ. Idarucizumab for dabigatran reversal. N Engl J Med2015; 373: 511–520.
12.
SchäferNMüllerAWüllnerU. Systemic thrombolysis for ischemic stroke after antagonizing dabigatran with idarucizumab – a case report. J Stroke Cerebrovasc Dis2016. doi 10.1016.
PollackCVJrReillyPABernsteinR. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost2015; 114: 198–205.
15.
KateMGioiaLBuckB. Dabigatran therapy in acute ischemic stroke patients without atrial fibrillation. Stroke2015; 46: 2685–2687.
16.
KateMSzkotakAWittAShuaibAButcherK. Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke. J Stroke Cerebrovasc Dis2014; 23: 1351–1355.
17.
HackeWKasteMFieschiC. for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet1998; 352: 1245–1251.
